Paradigm Biocapital Advisors LP Alkermes Plc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Alkermes Plc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,375,569 shares of ALKS stock, worth $43.3 Million. This represents 1.84% of its overall portfolio holdings.
Number of Shares
1,375,569Holding current value
$43.3 Million% of portfolio
1.84%Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
393Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$917 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$583 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$316 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$259 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$202 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.18B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...